Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.

Details

Ressource 1Download: Vaccines_CaseReport_boost_teriflunomide.pdf (308.07 [Ko])
State: Public
Version: author
License: Not specified
Serval ID
serval:BIB_05EF56B1FE9B
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Humoral Response Induced by Prime-Boost Vaccination with the ChAdOx1 nCoV-19 and mRNA BNT162b2 Vaccines in a Teriflunomide-Treated Multiple Sclerosis Patient.
Journal
Vaccines
Author(s)
Michiels Y., Houhou-Fidouh N., Collin G., Berger J., Kohli E.
ISSN
2076-393X (Print)
ISSN-L
2076-393X
Publication state
Published
Issued date
06/10/2021
Peer-reviewed
Oui
Volume
9
Number
10
Pages
1140
Language
english
Notes
Publication types: Case Reports
Publication Status: epublish
Abstract
Patients with multiple sclerosis (MS) are treated with drugs that may impact immune responses to SARS-CoV-2 vaccination. Evaluation of "prime-boost" (heterologous) vaccination regimens including a first administration of a viral vector-based vaccine and a second one of an mRNA-based vaccine in such patients has not yet been completed. Here, we present the anti-spike protein S humoral response, including the neutralizing antibody response, in a 54-year-old MS patient who had been treated with teriflunomide for the past 2 years and who received a heterologous ChAdOx1 nCoV-19/ BNT162b2 vaccination regimen. The results showed a very strong anti-S IgG response and a good neutralizing antibody response. These results show that teriflunomide did not prevent the development of a satisfactory humoral response in this MS patient after vaccination with a ChAdOx1 nCoV-19/ BNT162b2 prime-boost protocol.
Keywords
BNT162b2 vaccine, ChAdOx1 nCoV-19 vaccine, SARS-CoV-2, antibody response, teriflunomide
Pubmed
Open Access
Yes
Create date
09/10/2021 11:24
Last modification date
07/11/2021 6:41
Usage data